Veraxa Biotech F-1 Filing Registers 120 Million Shares for Resale

An F-1 filing is the registration statement a foreign private issuer files with the SEC to register securities for sale in the United States, and the F-1 filing from Veraxa Biotech, dated July 31, 2026, registers more than 120 million ordinary shares for resale by its early holders after a SPAC merger.

What happened

Veraxa Biotech AG is a Swiss oncology company based in Zurich. The registrant was named Veraxa Biotech Holding AG before the business combination, and EDGAR still lists the filer under that name. The company completed a business combination with Voyager Acquisition Corp., a special purpose acquisition company (SPAC), on June 10, 2026, and its ordinary shares now trade on the Nasdaq Global Market as VRXA. Its warrants trade on the Nasdaq Capital Market as VRXAW.

The preliminary prospectus does three things at once:

• It registers the issuance of up to 19,436,739 ordinary shares that could be delivered when warrants are exercised: 12,650,000 for public warrants and 6,786,739 for private warrants, each at an exercise price of $11.50.
• It registers the resale of up to 6,786,739 private warrants by their holders.
• It registers the resale of up to 120,295,385 ordinary shares by selling securityholders.

The resale block breaks down into 6,100,000 shares converted one-for-one from the SPAC’s Class B shares, 99,695,385 shares issued in the merger to company shareholders who are directors, officers or affiliates, 3,500,000 shares issued to Cantor under a fee modification agreement, and up to 11,000,000 shares issuable on the High Trail note and warrant.

On July 30, 2026 the shares closed at $1.96 and the warrants at $0.11.

How it works

The company says it will not receive proceeds from sales by the selling securityholders. It would receive cash only if warrant holders exercise for cash. Because the exercise price of $11.50 is far above the $1.96 share price, the prospectus says the company believes holders are unlikely to exercise while the shares trade below that level. Private warrants may also be exercised on a cashless basis.

The High Trail financing explains the 11 million shares in the last category. On May 27, 2026 the SPAC, Veraxa and affiliates of High Trail signed a securities purchase agreement for a $27.5 million senior secured note due 2027 and a four-year warrant with an initial exercise price of $11.50. The deal closed on June 15, 2026. The note runs 15 months and amortizes monthly starting six months after closing. Veraxa may pay each installment in cash, in registered shares or in a mix. The note is secured by all of Veraxa’s assets, which the prospectus flags as a limit on its ability to take on other secured debt.

On the business side, Veraxa says it has a clinical program in acute myeloid leukemia and two proprietary platforms for next-generation antibody drug conjugates and T cell engagers.

As a foreign private issuer and an emerging growth company, Veraxa may follow home-country governance practices in place of some Nasdaq rules, such as the majority-independent board requirement, and it files reduced periodic reports.

Key terms

• SPAC: a shell company that raises money in an IPO and later merges with a private business, taking it public.
• Selling securityholders: the holders named in the prospectus who may resell registered securities.
• Private warrants: warrants originally sold to a SPAC’s sponsor and underwriters, which can usually be exercised without paying cash.
• Senior secured note: debt that ranks ahead of other obligations and is backed by the borrower’s assets.
• Cashless exercise: exercising a warrant by taking fewer shares instead of paying the exercise price.

FAQ

Is Veraxa raising money in this filing? Not directly. The shares are registered for resale, and cash would come only from warrant exercises.

Why register so many shares? Shares issued in a merger are often restricted until a registration statement covers them. The registration lets the holders sell to the public once it is effective.

Has the filing been declared effective? The prospectus is marked subject to completion, so it is still preliminary.